PMID- 24137269
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 6
IP  - 3
DP  - 2013 Sep
TI  - Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk 
      myelodysplastic syndrome without 5q deletion.
PG  - 803-807
AB  - The aim of this study was to evaluate the efficacy and adverse effects of 
      lenalidomide in the treatment of intermediate-1 risk non-5q deletion [non-del 
      (5q)] myelodysplastic syndrome (MDS). A total of 30 patients with MDS were 
      classified through G-banding chromosome karyotype analysis and fluorescence in 
      situ hybridization (FISH). According to the International Prognostic Scoring 
      System scores, among the 30 patients, 23 and seven cases had scores of 0.5 and 
      1.0, respectively. Lenalidomide (Revlimid((R))), 10 mg/day) was administered for 21 
      days every 28 days. All 30 cases were treated with lenalidomide for at least 
      three cycles, including 20 cases with four cycles. The patients did not require 
      erythropoietin, cyclosporine or iron chelation treatments. Statistical analysis 
      was performed using SPSS statistical software version 13.0, and comparisons among 
      groups were conducted using a t-test. The efficacy of lenalidomide was 
      demonstrated in patients with intermediate-1 risk non-del (5q) MDS. Peripheral 
      blood cell counts were improved following treatment, and absolute neutrophil, 
      haemoglobin and platelet counts increased following 2-4 cycles of treatment. All 
      patients became stable having undergone three cycles of treatment; however, 17 
      patients with chromosomal abnormalities had no cytogenetic response to the 
      treatment, as confirmed through the FISH test. Patients with intermediate-1 risk 
      non-del (5q) MDS treated with lenalidomide did not achieve complete 
      haematological remission, although they demonstrated haematological improvement.
FAU - Yang, Yan
AU  - Yang Y
AD  - Department of Haematology and Oncology, The First Hospital of Jilin University, 
      Changchun, Jilin 130021, P.R. China.
FAU - Gao, Sujun
AU  - Gao S
FAU - Fan, Hongqiong
AU  - Fan H
FAU - Lin, Hai
AU  - Lin H
FAU - Li, Wei
AU  - Li W
FAU - Wang, Juan
AU  - Wang J
LA  - eng
PT  - Journal Article
DEP - 20130711
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC3786804
OTO - NOTNLM
OT  - lenalidomide
OT  - myelodysplastic syndrome
EDAT- 2013/10/19 06:00
MHDA- 2013/10/19 06:01
PMCR- 2013/07/11
CRDT- 2013/10/19 06:00
PHST- 2013/03/17 00:00 [received]
PHST- 2013/06/18 00:00 [accepted]
PHST- 2013/10/19 06:00 [entrez]
PHST- 2013/10/19 06:00 [pubmed]
PHST- 2013/10/19 06:01 [medline]
PHST- 2013/07/11 00:00 [pmc-release]
AID - etm-06-03-0803 [pii]
AID - 10.3892/etm.2013.1218 [doi]
PST - ppublish
SO  - Exp Ther Med. 2013 Sep;6(3):803-807. doi: 10.3892/etm.2013.1218. Epub 2013 Jul 
      11.